Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus XR dose escalation in African American renal transplant recipients
NCT04665310Phase 4Active, not recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Sep 2018
- Primary completion
- Jul 2025
- Modality
- RNA-Targeting Small Molecules
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in acute renal transplant rejection, sponsored by Houston Methodist Research Institute. Started Sep 2018; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
acute renal transplant rejection
Beyond the preview
Go deeper on NCT04665310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665310.